New Clinical Trial Will Evaluate Antibacterial Envelope in Cardiac Implantable Electronic Device Patients at Risk for Major Infections
Medtronic Announces First Patient Enrollment in the WRAP Infection Clinical Trial
MINNEAPOLIS – Jan. 7, 2015 – Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in the WRAP Infection Clinical Trial, which will evaluate the effectiveness of the TYRX™ Absorbable Antibacterial Envelope in reducing major infections in patients with cardiac implantable electronic devices (CIEDs) at risk for infection. The global clinical trial also will assess healthcare costs related to treatment of major infections in CIED patients. The first patient implant was performed by Edward J. Schloss, M.D., director of electrophysiology at The Christ Hospital in Cincinnati.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.